A detailed history of Yousif Capital Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Yousif Capital Management, LLC holds 28,288 shares of VRTX stock, worth $12.7 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
28,288
Previous 28,593 1.07%
Holding current value
$12.7 Million
Previous $13.4 Million 1.84%
% of portfolio
0.15%
Previous 0.16%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$460.0 - $505.78 $140,300 - $154,262
-305 Reduced 1.07%
28,288 $13.2 Million
Q2 2024

Jul 31, 2024

SELL
$392.81 - $485.53 $185,013 - $228,684
-471 Reduced 1.62%
28,593 $13.4 Million
Q1 2024

Apr 26, 2024

SELL
$407.69 - $446.08 $878,164 - $960,856
-2,154 Reduced 6.9%
29,064 $12.1 Million
Q4 2023

Feb 01, 2024

SELL
$343.0 - $410.68 $883,568 - $1.06 Million
-2,576 Reduced 7.62%
31,218 $12.7 Million
Q3 2023

Oct 30, 2023

SELL
$338.18 - $362.46 $295,231 - $316,427
-873 Reduced 2.52%
33,794 $11.8 Million
Q2 2023

Aug 02, 2023

BUY
$314.42 - $351.91 $190,538 - $213,257
606 Added 1.78%
34,667 $12.2 Million
Q1 2023

May 02, 2023

SELL
$283.23 - $323.1 $510,380 - $582,226
-1,802 Reduced 5.02%
34,061 $10.7 Million
Q4 2022

Jan 09, 2023

BUY
$285.76 - $321.48 $1.08 Million - $1.21 Million
3,777 Added 11.77%
35,863 $0
Q3 2022

Nov 04, 2022

SELL
$273.83 - $305.53 $73,112 - $81,576
-267 Reduced 0.83%
32,086 $9.29 Million
Q2 2022

Aug 01, 2022

SELL
$234.96 - $292.55 $213,813 - $266,220
-910 Reduced 2.74%
32,353 $9.12 Million
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $25,463 - $30,011
115 Added 0.35%
33,263 $8.68 Million
Q4 2021

Jan 31, 2022

BUY
$177.01 - $223.45 $5.87 Million - $7.41 Million
33,148 New
33,148 $7.28 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Yousif Capital Management, LLC Portfolio

Follow Yousif Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yousif Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Yousif Capital Management, LLC with notifications on news.